Search

Sana Biotechnology Inc

Gesloten

SectorGezondheidszorg

3.19 1.92

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.1

Max

3.24

Belangrijke statistieken

By Trading Economics

Inkomsten

-16M

-64M

EPS

-0.13

Werknemers

142

EBITDA

-17M

-61M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+155.59% upside

Dividenden

By Acuity

Volgende Winsten

4 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

268M

1.2B

Vorige openingsprijs

1.27

Vorige sluitingsprijs

3.19

Nieuwssentiment

By Acuity

25%

75%

34 / 339 Rangschikking in Healthcare

Sana Biotechnology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 sep 2026, 20:03 UTC

Correlated Moves

Sana Biotechnology Inc. is trading higher today, benefiting from strong market activity alongside Recursion Pharmaceuticals Inc. despite remaining below its 20-day moving average.

11 sep 2026, 23:46 UTC

Sana Biotechnology Inc. shares are higher in after-market hours, despite no specific news identified. Broader market context includes recent U.S. inflation data.

10 sep 2026, 20:07 UTC

News
Correlated Moves

Sana Biotechnology Inc shares are lower amid a broader biotechnology sector decline, influenced by rising Treasury yields and inflation concerns affecting market sentiment.

9 sep 2026, 23:01 UTC

Sana Biotechnology Inc. shares are higher in after-market hours, recovering from earlier declines amid unclear drivers for the price movement.

8 sep 2026, 20:03 UTC

News

Sana Biotechnology shares are declining despite a report on diabetes treatment advancements and a $25 million investment from Mayo Clinic.

4 sep 2026, 20:07 UTC

Sana Biotechnology Inc shares are lower amid broader market pressures following a strong jobs report, with no specific company news identified.

2 sep 2026, 20:08 UTC

Social Media
News

Sana Biotechnology Inc is advancing today amid gains in the Biotechnology sector and upcoming investor conferences focused on engineered cell therapies.

31 aug 2026, 20:07 UTC

Sana Biotechnology Inc. shares decline today, continuing a trend since Friday's close, amid broader market pressures from rising interest rate expectations.

28 aug 2026, 23:56 UTC

Sana Biotechnology Inc. shares advanced modestly higher in after-market trading, remaining near the upper end of their one-month range.

27 aug 2026, 23:02 UTC

Sana Biotechnology shares declined in after-market trading, reflecting a notable drop since Thursday's close, despite earlier gains earlier in the session.

26 aug 2026, 19:46 UTC

Sana Biotechnology Inc shares are higher today, trading near the upper end of their one-month range and above the 20-day moving average.

25 aug 2026, 23:16 UTC

Sana Biotechnology Inc shares are lower in after-market hours. Market sentiment was affected by a sharp decline in crude oil prices.

24 aug 2026, 19:36 UTC

Correlated Moves

Sana Biotechnology Inc's shares are lower today, reflecting broader declines in the biotech sector, including a drop in the ARK Genomic Revolution ETF.

21 aug 2026, 23:36 UTC

Sana Biotechnology Inc. shares moved lower in after-market trading, despite resilience in major stocks like Tesla and UnitedHealth. The price remains above its 20-day moving average.

20 aug 2026, 23:01 UTC

Sana Biotechnology Inc. shares are higher in after-hours trading, driven by gains in the Biotechnology sub-sector and remaining above its 20-day moving average.

19 aug 2026, 23:06 UTC

Sana Biotechnology Inc shares are lower in after-market hours, following a notable decline from earlier highs. No specific news was identified to explain the move.

18 aug 2026, 19:46 UTC

Sana Biotechnology Inc. shares are lower today, reflecting a decline since Monday amid rising Treasury yields and ongoing inflation concerns.

17 aug 2026, 23:46 UTC

Sana Biotechnology Inc shares are slightly higher in after-market hours. No specific news was identified to explain the movement.

14 aug 2026, 20:06 UTC

News

Sana Biotechnology shares declined amid mixed analyst ratings and broader market challenges, with BofA lowering its price target to $6.00 from $7.00.

13 aug 2026, 19:36 UTC

Sana Biotechnology Inc shares are lower today, continuing a decline since Wednesday. The price remains above its 20-day moving average.

12 aug 2026, 23:46 UTC

Sana Biotechnology Inc shares are lower in after-market hours, with no specific news identified to explain the price movement.

11 aug 2026, 19:31 UTC

News

Sana Biotechnology shares are higher following Q2 results showing an adjusted EPS of -$0.13, exceeding estimates, and a $25 million investment from Mayo Clinic.

10 aug 2026, 23:01 UTC

News

Sana Biotechnology Inc shares are lower in after-market hours following a second-quarter loss of $63.6 million, despite an adjusted EPS that exceeded expectations.

7 aug 2026, 19:56 UTC

Sana Biotechnology Inc. shares are higher, supported by broader market dynamics following a disappointing jobs report easing interest rate concerns.

5 aug 2026, 19:56 UTC

Sana Biotechnology Inc. is trading higher during Wednesday's session, having peaked earlier before pulling back slightly while remaining above its 20-day moving average.

4 aug 2026, 20:05 UTC

Sana Biotechnology Inc shares are higher, reflecting strong performance amid a decline in crude oil prices, which may ease inflationary pressures.

3 aug 2026, 19:46 UTC

Sana Biotechnology Inc is higher today, benefiting from a broader market rally, particularly in technology, despite earlier session pullbacks.

31 jul 2026, 23:06 UTC

Sana Biotechnology Inc shares are lower in after-market hours, retracing from earlier gains. Broader market trends show mixed sentiment among major tech firms.

30 jul 2026, 19:29 UTC

Sana Biotechnology Inc shares are higher today, recovering from earlier lows. The stock has shown an upward trend since Wednesday's close.

29 jul 2026, 23:36 UTC

Sana Biotechnology Inc shares are higher in after-market hours, reflecting a slight increase since Wednesday's close amid routine market activity and broader volatility.

Peer Vergelijking

Prijswijziging

Sana Biotechnology Inc Prognose

Koersdoel

By TipRanks

155.59% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8 USD  155.59%

Hoogste 12 USD

Laagste 6 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Sana Biotechnology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Sentiment

By Acuity

34 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat